Understanding TB Treatment

Mycobacterium tuberculosis can survive the onslaught of today's TB treatment, which takes six months to completely cure the disease.Not all tuberculosis bacteria are alike and their characteristics may change during treatment. Using innovative in vitro and in vivo systems PreDiCT-TB seeks to understand and find ways to measure these persistent organisms. These data will give insight into why current treatment takes so long and how to identify the best new combinations of drugs.

find out more

Enhancing preclinical development

There are many different approaches to preclinical evaluation of tuberculosis drugs, which may give information about different aspects of drug response. Optimising these models using the most innovative new technologies and understanding how they relate to each other and to the overall development pathway for combinations of drugs is a major goal of PreDiCT-TB.

find out more

Optimising clinical trials

The performance of different combinations of drugs in preclinical models has never been directly compared with the results of clinical trials. PreDiCT-TB will explore a wide range of preclinical systems and assemble a comprehensive database of clinical data relating to the most important combinations of drugs. This will enable us to optimise the development pathway and to use preclinical information in an integrated modelling framework to design the most effective early clinical trials possible.

find out more
Photographer: Eric Strömberg

Building effective partnerships

PreDiCT-TB is pioneering a broad multidisciplinary approach to development of combinations of tuberculosis drugs. We beleive that only through the interaction of mycobacteriologists,pharmacologists, clinical triallists, engineers and mathematical modellers will we find the solutions that are needed to bring new treatments to the clinic as quickly as possible.

find out more


The PreDiCT-TB Consortium has now ended.

However, if you have any questions regarding the project or the contents of this website, please contact Louise Cooper in the first instance at louise.cooper@liverpool.ac.uk.

find out more

Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis. It usually affects the lungs causing coughing,fever and weight loss. Although the disease has long been both preventable and curable, someone still dies from tuberculosis somewhere in the world every twenty seconds. Treatment still requires six months or more of combinations of antibiotics to ensure complete cure and more effective drugs are urgently needed to shorten treatment. The goal of the PreDiCT-TB consortium is to find the most rapid and reliable ways of identifying the most potent combinations of new drugs and hasten their arrival in the clinic.  To find out more about the project, please click here to view our flyer.


Find out more

Latest Developments

Consortium Partners

PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia

View More

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.